Chemotherapy for high-grade gliomas by Galanis, E & Buckner, J
High-grade gliomas are malignant neoplasms with high propensity
for local recurrence. Despite combined modality treatment
including surgical resection and radiation, a minority of patients
live beyond 2 years and for tumours such as glioblastoma multi-
forme, the median survival is less than 1 year (Lesser and
Grossman, 1994). Since the introduction of nitrosoureas in the
early 1970s, a large number of clinical trials have examined the
role of chemotherapy both after surgery and in the setting of recur-
rent disease. Frequently disappointing results, as discussed in this
review, led to questioning of the role of chemotherapy in the
management of patients with high-grade gliomas.
Improvement of chemotherapeutic options in neuro-oncology is
hampered by both the efficacy of the available agents as well as
methodological problems. The most obvious obstacle to effective
chemotherapy for high-grade gliomas remains the intrinsic
chemoresistance of these tumours to available agents (Petersdorf
and Berger, 1996). The role of the blood–brain and blood–tumour
barriers in preventing adequate drug concentration in the tumour
remains uncertain (Mak et al, 1995). While lipophilic small mole-
cules with low-binding fraction to the serum proteins seem to be
better suited for this purpose, the role of blood–brain barrier was
most likely overemphasized in the past. This is indirectly
suggested by the increased contrast enhancement of high-grade
gliomas, indicating a defective blood–brain barrier. In addition,
high response rates achieved with agents that do not easily cross
the blood–brain barrier, such as cisplatin in patients with
chemosensitive central nervous system (CNS) tumours, i.e.
embryonal tumours of the CNS (Galanis et al, 1997) and germ cell
tumours (Sebag-Montefiore et al, 1992) underscore the impor-
tance of chemoresponsiveness rather than blood–brain barrier as
being a major determinant of brain tumour response to
chemotherapy. In addition, the pharmacokinetics of agents
employed for the treatment of high-grade gliomas can be affected
in patients who are on anticonvulsants as a result of the induction
of hepatic oxidation and activation pathways (such as cytochrome
p450). These drug interactions may lead to suboptimal drug
concentrations as has been shown for paclitaxel (Chang et al,
1998), 9-aminocamptothecin (Grossman et al, 1998) and dacar-
bazine (Safgren et al, 1998).
Another fundamental question that has not yet been fully
addressed is whether or not conventional oncologic criteria of
response are useful and true measures of chemotherapy efficacy in
gliomas. The poor correlation between responses measured in
phase II studies and survival in adjuvant studies suggest that this
methodology may be problematic. A definition of response similar
to that for tumours outside the CNS provides a common language;
however, it is not clear if tumour response translates into improve-
ment in duration or quality of patient survival. Factors which
affect interpretation of response in the brain include prior surgery,
radiation therapy, corticosteroids and variability in scan tech-
niques. It is possible that the criteria currently in use may not
measure true tumour response to the same extent in the brain as in
tumours outside the CNS. Alternatively, high-grade gliomas are
not particularly chemosensitive tumours and it may be that we
accept too low a threshold of response as evidence of efficacy
(Brada and Sharpe, 1996). With these points in mind, we will
review the available data on chemotherapy for high-grade gliomas
in the adjuvant/neoadjuvant setting and for recurrent disease. The
focus of this review is to look critically at the available evidence in
order to determine the optimal use of chemotherapy for high-grade
glioma patients. In addition, we will expand on newer investiga-
tional directions that may lead to advances in future treatments.
GLIOBLASTOMA MULTIFORME/ANAPLASTIC
ASTROCYTOMA: ADJUVANT CHEMOTHERAPY
Unlike adjuvant treatment in other oncological fields, adjuvant
chemotherapy in high-grade gliomas does not imply the absence
of residual disease at the time of treatment. Furthermore, adjuvant
treatment does not attempt to prevent distant metastases but rather
aims toward better local control. Introduction of the nitrosoureas
in the 1970s remains the earliest and most significant chemo-
therapy contribution to the treatment of malignant glioma to date.
Two groups of investigators simultaneously reported phase II data
indicating that BCNU is active in patients with recurrent tumours,
Review
Chemotherapy for high-grade gliomas
E Galanis and J Buckner
Division of Medical Oncology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Keywords: chemotherapy; high-grade gliomas; glioblastoma multiforme; anaplastic astrocytoma; oligodendroglioma; oligoastrocytoma
1371
Received 13 January 1999
Revised 15 July 1999
Accepted 15 November 1999
Correspondence to: E Galanis
British Journal of Cancer (2000) 82(8), 1371–1380
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.1999.1075, available online at http://www.idealibrary.com on albeit in the era prior to computerized tomography (CT) or
magnetic resonance imaging (MRI) (Walker and Hurwitz, 1970;
Wilson et al, 1970). Subsequently, the Brain Tumor Study Group
(BTSG) in 1978 reported the results of a clinical trial (BTSG
6901) comparing the best conventional supportive care with
carmustine-[1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)] and
radiotherapy (RT) either alone or in combination. The median
survival of the patients in the support-only group was 14 weeks as
compared to 19 weeks in the BCNU-alone group, 36 weeks in the
RT-alone group and 35 weeks in the RT/BCNU group. Survival
curves for the patients receiving radiotherapy alone and for those
receiving carmustine plus radiation therapy were not significantly
different. Although survival distribution curves were practically
identical for the first 12 months from initiation of treatment, there
was a greater survival rate at 18 months among the patients
receiving the combination of carmustine plus radiotherapy with
10% still alive at that time, as compared to only 4% of patients in
the radiation-alone group (Walker et al, 1978). The BTSG trial
7201 confirmed the survival advantage that the combination of RT
and nitrosourea-based chemotherapy offered at 18 months. In that
study, methyl CCNU (semustine) alone proved to be significantly
worse as compared to RT, RT + BCNU, and RT + meCCNU
(Walker et al, 1980). However, the difference between nitrosourea/
RT arms and radiation alone was not statistically significant,
possibly secondary to small sample size, and no difference in
median survival was observed. The BTSG trial 7501 randomized
patients to receive in addition to 6000 rads of radiotherapy one of
four treatment regimens: carmustine (BCNU), high-dose methyl-
prednisolone (400 mg/m2 per day for 7 days every 3 weeks),
procarbazine, or BCNU + high-dose methylprednisolone. With the
exception of RT + high-dose methylprednisolone, all other arms
were equivalent in terms of median survival and percentage of
patients alive at 18 months (Germain and Margulies, 1993). Thus,
this study proved that high-dose steroids do not have an anti-
tumour effect and that using steroids in amounts considerably
higher than those required for elimination of cerebral oedema and
symptom control does not increase survival.
Levin et al (1990) performed a phase III comparison of BCNU
and the combination of procarbazine, CCNU and vincristine
(PCV) administered after radiotherapy with hydroxyurea for
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Table 1 Phase III trials of adjuvant therapy of malignant gliomas
Treatment n Results Reference
BTSG Trial 6901
BCNU 222 Improved survival for patients Walker et al, 1978
RT receiving RT and BCNU + RT vs BCNU
BCNU + RT or best supportive care
Supportive care
BTSG Trial 7702 557 No significant difference among the arms Deutsch et al, 1989
RT + BCNU
RT + misonidazole + BCNU
RT + streptozotocin
Hyperfractionated RT + BCNU
BTSG Trial 8001 510 No significant difference among the arms Shapiro et al, 1989
RT + BCNU
RT + BCNU/procarbazine
RT + BCNU +
hydroxyurea/procarbazine + VM-26
RTOG/ECOG Trial 7401 554 No significant difference among the arms. Chang et al, 1983;
RT Overall improved survival in patients 40–60 Nelson et al, 1988
RT + RT boost years with chemotherapy + RT
RT + BCNU
RT + MeCCNU + DTIC
NCCTG 346 No significant difference among the arms. Dinapoli et al, 1993
RT + PCNU BCNU – more haematologic toxicity.
RT + BCNU PCNU – more GI toxicity
RTOG 7918 293 No significant difference between the Nelson et al, 1986
RT + BCNU arms. Misonidazole produced peripheral
RT + misonidazole + BCNU neuropathy
SW0G Trial 7703 278 BCNU + DTIC arms had better response Shapiro et al, 1992
RT + BCNU rates compared to procarbazine arms (39
RT + Procarbazine and 38% vs 13%). No
RT + Dacarbazine (DTIC) statistically significant difference in
survival
SWOG Trial 7404 115 No significant difference between the Eyre et al, 1983
RT + CCNU arms
RT + CCNU + Procarbazine
NCCTG 238 Somewhat higher but no statistically Elliott et al, 1997
RT + BCNU significant different failure rates in the
RT + dibromodulcitol (DBD, DBD arm
halogenated hexitol functioning as
alkylator)malignant gliomas. A total of 133 patients were randomized; 73
with anaplastic gliomas and 60 with glioblastoma multiforme (29
at the BCNU arm, 31 at the PCV arm). The PCV combination
produced longer overall survival and time to tumour progression
than BCNU for both histologic groups, although the difference
was statistically significant only for the anaplastic gliomas.
Median survival was 82.1 weeks in the BCNU arm versus 157.1
weeks in the PCV arm. Prognostic covariates such as age, perfor-
mance status and extent of surgical resection were balanced
between the two histologic strata and two treatment groups. One of
the pitfalls of this trial, however, is the inclusion of oligoden-
droglial-containing tumours in addition to anaplastic astrocy-
tomas. Subsequently, in patients with anaplastic astrocytomas, the
RTOG 9404 trial compared RT + PCV versus RT + PCV + the
radiosensitizer BUdR. So far no difference in survival between the
two arms has been detected (Prados et al, 1997).
Additional phase III adjuvant chemotherapy studies that have
failed to show survival benefit of other chemotherapy regimens
compared with BCNU + RT are summarized in Table 1. Of note in
all of these trials, anaplastic astrocytomas were grouped together
with glioblastoma multiforme.
The Medical Research Council recently reported in an abstract
form on a prospective, randomized trial of adjuvant radiation
therapy versus radiation therapy plus PCV in high-grade glioma
patients < 70 years of age (MRC-BR05). With a median follow-up
of 1 year and 674 patients enrolled, there was no significant differ-
ence in median survival between the radiation therapy and the
combined treatment arm (Bleehen et al, 1998).
Of note, in all the prospective randomized high-grade glioma
adjuvant therapy trials, where RT alone was one of the treatment
arms, there was either no difference between the RT alone and the
RT plus nitrosourea arms (i.e. BTSG trial 7201 (Walker et al, 1980)),
or there was a statistically significant difference, but only in the long-
term (18 months and overall survival, such as in the BTSG trial 6901
(Walker et al, 1978) or in the RTOG 7401-ECOG 1374 (Change et
al, 1983; Nelson et al, 1988)). A potential explanation of the margin-
ally significant results may have been the relatively small number of
patients in some of the trials. To have an 80% probability of
detecting a 25% increase in median survival at the 5% significance
level, one would need a clinical trial following 250 patients per arm
until death. The BTSG trials which were among the largest multi-
institution studies had fewer than 150 patients in each treatment arm.
Most single-institution studies have had fewer than 50 patients per
treatment arm. Using the results from 16 randomized clinical trials
involving more than 3000 patients, Fine et al (1993) performed a
meta-analysis of radiation therapy with and without adjuvant
chemotherapy for malignant gliomas in adults. The estimated
increase in survival for patients treated with combination radiation
and chemotherapy was 10.1% at 1 year and 8.6% at 2 years. This
absolute increase in survival in patients treated with chemotherapy
represents relative increases of 23.4% at 1 year survival and 52.4% at
2 years’ survival. When the prognostic variables of age and histology
were incorporated in the analysis, the data suggested that the survival
benefit from chemotherapy appeared earlier in patients with
anaplastic astrocytoma than in patients with glioblastoma multi-
forme: the maximal survival advantage was seen at 12–18 months
for patients with anaplastic astrocytoma versus 18–24 months for
patients with glioblastoma. There were methodological problems
associated with this meta-analysis, the most important being the use
of reported clinical trial results, some of which were incomplete,
rather than individual patient data to perform the analysis.
The route of chemotherapy administration was assessed in the
BTSG trial 8301 (Shapiro et al, 1992). Patients with newly
resected malignant glioma received either intra-carotid BCNU or
intravenous BCNU with or without intravenous 5-fluorouracil
(5-FU). All patients also received radiation therapy. Intravenous
BCNU was significantly better than intra-arterial BCNU
(P = 0.03), mainly because of the serious toxicity that was
observed in the intra-arterial group; 16 patients (9.5%) developed
irreversible encephalopathy with CT evidence of cerebral oedema,
and 26 patients (15.5%) developed visual loss ipsilateral to the
infused carotid artery. Administration of 5-FU did not influence
survival. The survival rate between GBM patients treated with
intravenous vs intra-arterial BCNU did not differ, but it was worse
for patients with anaplastic astrocytoma treated with intra-arterial
BCNU than for those receiving intravenous BCNU (P = 0.009).
Similarly, a phase II SWOG study of intra-arterial administration
of cisplatin concomitant with or before radiation therapy led to
thromboembolic problems in 14% of the courses. Five of 27
patients died prior to treatment completion (Mortimer et al, 1992).
The value of adjuvant chemotherapy varies according to age and
tumour grade. Long-term follow-up of the RTOG 7401-ECOG 1374
trial (18) showed that for patients aged 40–60 years there was statis-
tically significant increase in overall survival when BCNU was
added to 6000 cGy (P < 0.01) with an increase in 2-year survival
from 8 to 23%. For patients older than 60 years of age, the addition of
chemotherapy to radiation therapy did not improve survival. In the
40–60 year age group, the beneficial effect of BCNU was apparent in
both histological groups (anaplastic astrocytoma and glioblastoma
multiforme). Although few confirmatory autopsies were available,
long-term survival in patients with anaplastic astrocytomas who were
treated with 6000 cGy + BCNU suggested no significant additional
CNS toxicity compared to 6000 cGy alone (Nelson et al, 1988).
While designed to compare the efficacy of different treatment
modalities in the adjuvant setting, multiple prospective random-
ized trials have also identified association among specific prog-
nostic variables and the survival time for these patients. These
include histologic grade and type, age and performance score
(Karnofsky or ECOG). Glioblastoma multiforme patients survive
approximately half as long as those harbouring anaplastic astrocy-
toma. Patients older than 60 have a significantly shorter survival
regardless of the grade of tumour. Patients with Karnofsky score
above 90 have one-third the death rate of patients with ratings of
40 or below (Walker et al, 1980; Germain and Margulies 1993).
Some investigators have also reported that extent of tumour resec-
tion as estimated by the neurosurgeon provides prognostic infor-
mation. Patients who undergo gross total tumour resection fare
better than those with subtotal resection or biopsy alone. The
improvement may be explained partially by tumour size and loca-
tion; that is, patients with smaller tumours in non-eloquent brain
may fare better, regardless of surgical procedure.
The value of neoadjuvant chemotherapy administered prior to
surgery or prior to radiation therapy in high-grade gliomas remains
an open question. Radiation-induced changes to the integrity of the
blood–brain barrier make it very difficult to evaluate the efficacy of
the chemotherapy administered during or shortly after radiation
therapy even in patients with measurable disease. Neoadjuvant
chemotherapy has the potential to greatly enhance the discovery of
truly active agents as well as the early identification of ineffec-
tive therapies in a disease where chemotherapy has been only
marginally effective. In a phase II setting, Grossman et al adminis-
tered BCNU and CDDP as a 72-h continuous intravenous infusion
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studied, 42% had a partial response and 53% had stable disease.
Only two patients (4%) developed progressive disease while on
treatment. The 1- and 3-year survival rates were 64% and 12%
respectively. Similar results were reported by Gilbert et al (1993).
In order to address this question definitively, two current
intergroup phase III trials (NCCTG/SWOG 93–72–52 and
ECOG/SWOG 2394) compare BCNU + CDDP at different doses
and schedules either prior to or concomitantly with radiation. Both
trials will assess the effect of chemotherapy administered prior to
radiation therapy in glioblastoma patients. The NCCTG/SWOG
study completed accrual in June 1999 and the first analysis of the
data is anticipated by the end of the year 2000.
In summary, chemotherapy has a limited role in the manage-
ment of newly diagnosed patients with high-grade astrocytomas.
Nitrosourea-containing regimens administered with and after
radiation therapy appear to produce modest survival advantage in
younger (< 60 years of age) GBM patients in some but not all
studies and in patients with anaplastic astrocytomas. Intra-arterial
administration of BCNU and cisplatin appears to result in unac-
ceptable toxicity. The effectiveness of combination regimens
containing both cisplatin and nitrosoureas and the value of neo-




In the recent years, anaplastic oligodendrogliomas have been iden-
tified as particularly sensitive to chemotherapy, as compared to
astrocytomas. Cairncross and Macdonald in 1988 reported on
use of nitrosourea-based chemotherapy mainly PCV for treatment
of recurrent anaplastic oligodendroglioma (Cairncross and
Macdonald, 1988, 1991; Cairncross et al, 1992). In a small series
of eight patients, all patients responded to chemotherapy including
two with systemic metastasis. The median duration of response in
these previously irradiated patients was 15 months (range 8–36
months). The same authors reported responses to PCV adminis-
tered before radiation therapy in patients with newly diagnosed
aggressive oligodendrogliomas and measurable disease after
initial surgery (Macdonald et al, 1990). These studies led to a
multicentre phase II study in which patients with measurable
newly diagnosed or recurrent contrast-enhancing anaplastic
oligodendrogliomas were treated with up to six cycles of PCV
(Cairncross et al, 1994). Of 24 eligible patients, 18 (75%)
responded, nine completely (38%), four had stable disease and two
progressed during the first cycle of PCV. Previously irradiated
patients were as likely to respond to PCV as newly diagnosed
(11 of 15 (75%) versus 7 of 9 (78%)). The median time to progres-
sion was at least 25.2 months for the complete responders,
14.2 months for partial responders, and 6.8 months for stable
patients.
The role of adjuvant chemotherapy for patients with oligo-
dendroglioma remains uncertain. Based on promising results in
patients with either newly diagnosed or recurrent disease, an inter-
group study (RTOG 9402) is in progress comparing radiation
alone vs four cycles of PCV followed by radiation in patients with
anaplastic oligodendroglioma/oligoastrocytoma.
In addition to PCV, other chemotherapy agents are active
against oligodendrogliomas such as melphalan (Green et al, 1983;
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Table 2 Selected chemotherapy trials for recurrent and progressive astrocytomas
Pretreated Median
Total patients AA/GBM Response survival
Agent patients (%) (%) (%) (weeks) Reference
Nitrosourea regimens
BCNU 91 – – 31 16 Broder and Carter, 1970
CCNU 116 – – 30 22 Hoogstraten et al, 1973
BCNU + AZQ 42 50 24/76 21GB, 30AA 23 Yung et al, 1989
BCNU + PCBZ 45 – – 29 – Gutin et al, 1975
BCNU + IFN-a 35 0 – 26 52 Buckner et al, 1989
CCNU + procarbazine + vincristine 46 58 26/26 29 – Levin et al, 1980
PCBZ-containing regimens
PCBZ 99 96 37/46 28 – Rodriguez et al, 1989
PCBZ + VCR + Thiotepa 20 100 20/80 15 52 Ameri et al, 1993
MOP 27 29 22/62 52 20GB, 81AA Coyle et al, 1990
Platinum-containing regimens
CDDP 45 100 – 17 20 Spence et al, 1992
CBDCA 34 100 50/50 11 24 Yung et al, 1991
CDDP + VP16 33 100 31/69 17 24 Buckner et al, 1990
CBDCA + VP16 38 100 21/79 21 47.5 Jeremic et al, 1992
CBDCA + VP16 + Ifosfamide 36 100 22/72 28 29 Sanson et al, 1996
Other regimens
AZQ 68 38 32/68 26 22 EORTC, 1985
Melphalan 30 100 46/54 3 8 Chamberlain et al, 1988
Ifosfamide 16 100 50/50 0 19 Elliott et al, 1991
VM26 20 100 – 20 24 Kessinger et al, 1979
VP16 35 100 54/46 17 18 Tirelli et al, 1984
Fludarabine 15 53 45/55 3 19 Cascino et al, 1988
Paclitaxel 20 100 40/40 20 – Chamberlain and Kormanik, 1995
BCNU = carmustine, CCNU = lomustine, PCBZ = procarbazine, AZQ = aziridinylbenzoquinone, CDDP = cisplatin, CBDCA = carboplatin, NP26 = teniposide,
VP16 = etoposide, IFN-a = interferon-alpha, MOP = mechlorethamine, vincristine, procarbazine, VCR = vincristine.Brown et al, 1990), BCNU and AZQ (Cairncross and Macdonald,
1988). Data examining the role of these agents as salvage
chemotherapy in patients who have failed PCV are limited. While
PCV has been proven to have activity in patients who have previ-
ously responded to AZQ or received adjuvant BCNU therapy, the
opposite does not always hold true. AZQ and cisplatin were inef-
fective in four patients who relapsed after PCV, while two patients
who had previously responded to PCV had brief partial responses
after intravenous treatment with melphalan (Brown et al, 1990).
As a result, there is no standard second-line treatment for patients
with recurrent disease who have failed PCV.
Anaplastic oligoastrocytoma patients are usually treated simi-
larly to those with pure oligodendroglioma. Glass et al (1992) and
Kyritsis et al (1993) have reported that oligoastrocytomas also
respond predictably to PCV with objective response rates of 64%
and 42%, respectively, in newly diagnosed tumours. Similarly,
oligoastrocytoma patients treated with PCV at first relapse had a
median time from recurrence to death of 5.6 years, while the
median relapse-free survival was 1.3 years (Kyritsis et al, 1993).
CHEMOTHERAPY FOR RECURRENT HIGH-
GRADE ASTROCYTOMAS
Different agents and combinations have been employed in phase II
trials for treatment of recurrent and progressive supratentorial
astrocytomas (Table 2), but results have been quite disappointing.
Response rates are low and time to progression is short, varying
from a few to several months. Nitrosoureas have the most consis-
tent activity with response rates ranging from 21 to 31% (Table 2).
The overwhelming majority of chemotherapy trials for patients
with recurrent high-grade glioma include both patients with
anaplastic astrocytoma and glioblastoma multiforme. Of note,
some of the studies referenced in Table 2 were conducted in the
pre-CT era and the results should be viewed with caution since
response was often assessed based on clinical criteria only. In addi-
tion, results reported regarding paclitaxel as summarized in Table
2 may represent an underestimation of the actual drug activity
since doses employed were subtherapeutic for patients on anticon-
vulsants. The same applies for topoisomerase-I inhibitors such as
9-AC (Grossman et al, 1998). Encouraging results were also
reported with the use of MOP combination (mechlorethamine,
vincristine, procarbazine) in recurrent malignant glioma patients,
including a response rate of 37% in glioblastomas and 100% in
anaplastic astrocytoma (Coyle et al, 1990). Unfortunately, these
results could not be reproduced in a recent larger NCCTG study
(Galanis et al, 1998). Although phase III comparison data are not
available, as Table 2 indicates, there is no consistent evidence
that any combination is superior to single-agent nitrosourea
chemotherapy for patients with recurrent gliomas.
Given the increasingly widespread use of nitrosoureas in the
adjuvant setting for both anaplastic astrocytomas and glioblastoma
multiforme, options at the time of relapse are even more limited.
Consideration could be given to the use of procarbazine in patients
who failed BCNU in the adjuvant setting. In one series of 99 high-
grade glioma patients (96 of whom were pretreated), single-agent
procarbazine resulted in a response rate of 28% (Rodriguez et al,
1989). Platinum compounds may also offer limited benefit with
response rates ranging from 11 to 21% (Buckner et al, 1990; Yung
et al, 1991; Jeremic et al, 1992; Spence et al, 1992). More recently,
interesting results were obtained with the ICE regimen (ifos-
famide, carboplatin and etoposide) in a series of 36 well-defined
patients who were all pretreated with surgery, irradiation and
nitrosourea-based chemotherapy. Five complete responses (CR)
and five partial responses (PR) were reported with an overall
response rate of 28%. Unfortunately, median survival (29 weeks)
for all patients remained low despite a median survival of 44
weeks for the responders, and it was achieved at a price of severe
haematologic toxicity (Sanson et al, 1996).
Dacarbazine is another agent that has been reported to have
activity against recurrent glioma. However, a recently completed
NCCTG study indicated a response rate of less than 5% when dacar-
bazine was employed in patients with recurrent gliomas (unpub-
lished data). There has also been considerable interest in
temozolomide, an imidotetrazine analogue of dacarbazine (DTIC).
Unlike dacarbazine, temozolomide does not require hepatic activa-
tion, and it displays excellent oral bioavailability (Newlands et al,
1997). Based on encouraging responses observed during phase I
studies (Newlands et al, 1992), temozolomide was administered to
48 patients with recurrent glioma after radiotherapy. Objective
clinical radiologic responses were reported in 25% of the patients
(Newlands et al, 1996). In another multicentre phase II study in
patients with progressive or recurrent supratentorial high-grade
gliomas, 11% of the patients achieved objective response with a
median duration of 4.6 months and another 47% had stable disease
(Bower et al, 1997). In a phase III study comparing temozolomide
with procarbazine in patients who have failed nitrosourea-based
chemotherapy for recurrent glioblastoma multiforme, temozolomide
led to a response rate of 4.7% and a response duration of 85 days as
compared to a response rate of 3% for procarbazine and a response
duration of 99 days. There was a statistically significant difference
in progression-free survival favouring the temozolomide arm.
However, there was no significant difference in median or overall
survival. Preliminary quality-of-life analysis data seemed to indicate
that quality-of-life until progression was better in the temozolomide
arm (Yung et al, 1999). In a phase II trial of 162 patients with recur-
rent anaplastic astrocytomas, temozolomide led to a response rate of
35%, while 27% of the patients had stable disease (Prados et al,
1999). The 6- and 12-month progression-free survival was 46% and
24% respectively. The response was highest for patients who had not
received prior chemotherapy (39%) and lower for patients who
received prior nitrosoureas with or without procarbazine (22%).
Temozolomide has been approved for patients with recurrent GBM
in Europe and with recurrent anaplastic astrocytoma in the US, the
latter approval being contingent upon confirmatory data.
Combination studies with cis-retinoic acid, inter-feron alpha
nitrosoureas (BCNU) and radiation are underway (Levin, 2000;
Newlands 1997a; Newlands 1997b). Finally, ongoing trials will
address the role of temozolomide as a single agent or in combination
with BCNU for newly diagnosed anaplastic astrocytoma patients.
Recently published results also indicate that the topoisomerase I
inhibitor CPT-11 does have activity in patients with recurrent
disease. In a study of 60 patients, 48% of whom had received prior
nitrosourea-based chemotherapy, a 15% partial response rate was
observed. The median survival was 42 weeks for the 48 patients
with GBM and not reached yet (more than 40 weeks) for the ten
patients with anaplastic astrocytoma. The low incidence of severe
toxicity and low plasma concentration of CPT-11 and its metabo-
lite SN-38 suggested that concurrent treatment within anticonvul-
sants or dexamethasone may have enhanced drug clearance
(Friedman et al, 1999).
Despite the large number of phase II studies and continued use
of chemotherapy in patients with recurrent high-grade glioma,
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this setting is not easy to find. This may be due either to the diffi-
culty of measuring quality of life and functional status in brain
tumour patients or simply to the absence of planned evaluation of
these parameters as a measure of efficacy. With new quality of life
scales (Osaba et al, 1996) and functional indices (Grant et al,
1994) this should no longer be an obstacle.
Controlled release of biodegradable polymers also provides a
novel approach. Two polyanhydride systems have been studied
extensively; p(CPP-SA) for hydrophobic drugs such as BCNU;
p(FAP-SA) for hydrophilic compounds, and those susceptible to
hydrolysis such as methotrexate and cisplatin (Brem et al, 1992;
Domb et al, 1991). Brem et al (1992) have established the safety of
this methodology. In a recent randomized placebo-controlled trial
of 222 patients with recurrent gliomas, 6-month survival was
greater in glioblastoma patients treated with BCNU wafers than in
the placebo group (64% vs 44%) (Brem et al, 1995). Despite a
trend favouring the BCNU implant group, the differences in
median and overall survival did not reach statistical significance.
In a multiple regression analysis model, carmustine polymer
showed a significant beneficial effect in recurrent glioblastoma
patients (hazard ratio = 0.67, P = 0.02) (Brem et al, 1995). Future
studies employing this technology will examine the utility of
BCNU-polymer therapy in newly diagnosed patients, the efficacy
and toxicity of escalating doses of BCNU, and the effects of other
cytotoxic drugs delivered in this fashion.
Autologous bone marrow transplantation (ABMT) has had few
practitioners generally because of the low response rate of high-
grade gliomas to any form of chemotherapy. Use of high-dose
BCNU (800 mg/m2 to 1400 mg/m2) resulted in responses in
33–44% of the patients and treatment-related deaths in 17–32% of
the patients mainly because of infection complications, interstitial
pneumonitis and drug-induced severe hepatitis (Phillips et al,
1986). Overall, none of those studies have shown a significant
benefit as compared to conventional dose of nitrosourea therapy
(Phillips et al, 1986; Giannone and Wolff, 1987; Fine and Antman,
1992). Similarly, the use of high-dose etoposide in the setting of
ABMT (1000–2400 mg/m2) resulted in a response rate of 19% and
a toxic death rate of 15% (Giannone and Wolff, 1987).
In summary, nitrosourea-based regimens can be considered as
standard first-line treatment for patients with recurrent high-grade
gliomas who have not received prior nitrosoureas. The superiority
of combination regimens, of nitrosourea-based, to single-agent
nitrosoureas in this setting has not been proven. For patients who
have failed prior nitrosoureas, chemotherapy approaches include
temozolomide, procarbazine, platinum compounds and possibly
CPT-11. Given the limited efficacy of all available treatments for
recurrent high-grade gliomas, participation in phase II or III clin-
ical trials should be encouraged.
FUTURE DIRECTIONS
The lack of effective curative treatments for most high-grade
glioma patients has led to several efforts for development of new
therapeutic approaches. In recent years, explosive development of
molecular biology techniques has allowed the molecular charac-
terization of high-grade gliomas. In addition, the role of pharma-
cologic approaches employing small molecules as well as gene
transfer techniques aiming at specific molecular targets is
currently under assessment in clinical trials. It is the authors’ hope
that, in the future, molecular/genetic characterization of high-
grade gliomas will allow use of individualized rational treatments
depending on the tumour’s genetic make-up. In addition, emerging
data on the role of angiogenesis in tumour invasion and the
challenge of the dogma that CNS represents an immunologic
sanctuary may lead to new approaches in the treatment of high-
grade gliomas. In this process, a lot remains to be learned about
interactions and integration of these newer approaches with
traditional methods used in the treatment of high-grade gliomas
such as surgery, radiation therapy and conventional chemotherapy
regimens.
Chemotherapeutic agents
The explosive development of small molecules targeting cell cycle
signalling opens new directions in the treatment of high-grade
gliomas. Figures 1 and 2 describe cytogenetic changes as well as
cell cycle regulators with possible pathogenetic importance in the
development of high-grade malignant gliomas. Among these
agents currently in preclinical or early stages of clinical develop-
ment are rapamycin analogues that inhibit the action of protein
kinase m-TOR or FRAP (Beretta et al, 1996), farnesyl transferase
inhibitors (Kohl et al, 1993), and tyrosine kinase inhibitors such as
tyrphostins (Yoneda et al, 1991; Siu et al, 1999; Karp et al, 1999;
Yung et al, 1999). Tyrosine kinases may play an important role in
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Figure 2 Cell cycle regulators. Positive (+) and negative(-) regulators of
cyclin/CDK are indicated. Protein whose genes are altered in brain tumors
are shown in bold. (CDK = cyclin dependent kinase; TGF = transforming
growth factor, RB = retinoblastoma) (Reproduced with permission from
Galanis E and James CD (1999) Brain Tumors In: Molecular Biology in
Cancer Medicine, 2nd Edn, Kurzrock R and Talpaz M, (ed.)
Figure 1 Gene alterations associated with the development of malignant
gliomas. (Amp = amplification; LOH = loss of heterozygosity.) Reproduced
with permission from Galanis E and James CD (1999) Brain Tumors In:
Molecular Biology in Cancer Medicine, 2nd Edn, Kurzrock R and Talpaz M
(ed.)pathogenesis of malignant gliomas. For example, epidermal growth
factor receptor, an oncogene amplified in approximately 50% of
glioblastomas, has tyrosine kinase activity. Other approaches
targeting EGFR include monoclonal antibodies and antisense
oligonucleotides with EGFR mRNA being a potential target (80).
Another promising category of new small molecule pharmaceu-
ticals include anti-invasion molecules. Matrix metalloproteinases
are proteases overexpressed in tumours (Lampert et al, 1998) that
degrade macromolecules of the extracellular matrix and are
responsible for tumour invasion. Matrix metalloproteinase
inhibitors (MMPIs) such as marimastat are currently in early
stages of clinical development while other anti-invasion molecules
such as quinazoline derivatives (they inhibit glioblastoma cell
adhesion and activation and induce apoptosis in vitro) are under-
going preclinical testing (Krishna et al, 1998).
Phase II trials are also underway, trying to assess the effect of
the combination of O6-benzylguanine plus BCNU in patients with
recurrent high-grade gliomas. O6-benzylguanine inhibits
O6-alkylguanine-DNA alkyltransferase (AGT), a repair protein
that appears to predict resistance to nitrosoureas and other related
alkylators (Belanich et al, 1996; Dolan and Pegg, 1997).
Finally, the role of newer agents that increase the permeability
of blood–brain barrier to hydrophilic chemotherapy agents is
currently under investigation. The bradykinin analogue RMP-7
has been administered intravenously (Ford et al, 1998) or intra-
arterially (Cloughesy et al, 1999) in combination with carboplatin
and it is currently undergoing evaluation in phase II and III studies.
Angiogenesis inhibition
Glial tumours are characteristically hypervascular as endothelial
proliferation is a hallmark pathologic feature of high-grade glioma
(Burger et al, 1991). This neovascularization typically produces a
striking pattern of capillary tufts resembling renal glomeruli which
are found throughout the tumour (Russell and Rubinstein, 1989).
Glioma vasculature is usually abnormal, both from a structural as
well as a functional standpoint (Luse 1960; Kaye and Laws, 1995).
The presumed causal link between angiogenesis and prognosis via
metastasis which exists for extracranial tumours may or may not be
applicable to gliomas and other mechanisms by which angiogenesis
may directly affect the clinical course of gliomas must be postu-
lated. Foremost among these is the likelihood that aggressive local
growth is facilitated by intense angiogenesis. The issue of the prog-
nostic significance of angiogenesis in glial neoplasm is complex
and in need of further study as indicated by conflicting reports
regarding its prognostic significance and further complicated by the
fact that angiogenesis is by definition associated with increasing
tumour grade and poor prognosis (Burger et al, 1985; Cohadon et
al, 1985; Fulling and Gercia, 1985; Daums-Duportet al, 1988). A
number of factors have been implicated in glioma angiogenesis
including vascular endothelial growth factor (VEGF) (Plate et al,
1994), fibroblast growth factor (FGF) (Li et al, 1994), epidermal
growth factor (EGF) (Folkman and Klagsbrun, 1987), transforming
growth factors (TFG) (Folkman and Klagsbrun, 1987) and platelet-
derived growth factor (PDGF) (Folkman and Klagsbrun, 1987).
Anti-angiogenesis therapy for brain tumours offers several addi-
tional advantages as well as significant limitations not found in
extracranial neoplasms. The main advantage is that gliomas gener-
ally do not metastasize. Therapy targeted to local disease could
theoretically be effective. Also, the adult brain contains few
dividing cells (except perhaps endothelial cells themselves) and
does not under routine circumstances express normal angiogenesis
(Russell and Rubinstein, 1989).
Anti-angiogenesis therapy directed at highly vascular gliomas
might therefore be expected to be less toxic to the surrounding
brain. In addition, with sensitive modern imaging studies, tumour
growth and response to therapy can be followed non-invasively.
Agents with anti-angiogenesis potential currently or recently in
clinical trials include SU101 that blocks the angiogenetic function
of PDGF as well as VEGF by inhibiting a receptor tyrosine kinase.
A phase III study currently ongoing in the USA and Canada
compares SU101 with procarbazine in patients with recurrent
gliomas. Other agents currently in clinical trials are the fumagillin
analogue TNP-470 that appears to have very specific effects on
endothelial cell growth, producing cytostatic growth arrest
(Takamiya et al, 1994), and thalidomide (D’Amato et al, 1994). A
recently completed trial of thalidomide in patients with recurrent
high-grade gliomas, showed minimal antitumor activity (PR =
6%), although the drug was generally well tolerated (Fine 2000).
Finally, other potential agents include angiogenesis inhibitors,
angiostatin and endostatin (O’Reilly 1997; O’Reilly et al, 1997).
Gene therapy
Because intracranial recurrence rather than systemic metastases
characterizes the pattern of relapse in gliomas and brain tumours,
they became one of the first targets for human gene therapy for
cancer. Gene therapy research has evolved from the initial retro-
viral vectors to herpes virus vectors, adenoviral vectors and HSV
(herpes simplex virus)/AAV (adeno-associated virus) hybrid
vectors, in order to improve transduction rates, transgene capacity
and eliminate the possibility of neurotoxicity. Patients have been
treated by stereotactic intratumoural injections of fibroblasts
producing retroviral vectors that deliver the gene encoding the
enzyme HSV thymidine kinase with subsequent systemic ganci-
clovir treatment (Oldfield et al, 1993). Fifteen patients with
primary or metastatic brain tumours were entered in the first study.
MRI suggested regression in the volume of the gadolinium-
enhancing portion of the tumours in the early period after treat-
ment in eight patients. In four patients the enhanced tumour
portion was not detected for periods of 4–18 months. Despite the
low transduction efficiency (17%), bystander effect resulted in
additional killing of the tumour cells (Oldfield et al, 1993). In
order to give the patients the additional benefit of tumour
debulking, 30 patients with recurrent GBM had tumour resection
followed by cavitary injection of the vector producer cell line (GLI
328) and gancyclovir treatment. Five patients were alive at 17–32
months after resection (Berger et al, 1997). A phase III trial of GLI
328 in patients with newly diagnosed glioblastoma was recently
completed in multiple centres worldwide. Additional gene
delivery systems lately introduced in clinical trials for the treat-
ment of recurrent gliomas are an HSV-tk adenovirus and a replica-
tion defective p53 adenovirus (an approach justified based on the
high p53 mutation rate in high-grade gliomas, ranging between 25
and 50%). The fact that CNS gliomas rarely metastasize makes
them a good target for local delivery achieved through gene
transfer approaches; however, improvement of the available gene
delivery systems may be necessary to realize the full potential of
this treatment approach. Despite the presence of connexin medi-
ated gap junctions that facilitate the ‘bystander’ effect, the diffuse
invasion of the brain by high-grade glioma cells beyond imaging
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vectors problematic even when administered after optimal surgical
debulking. A possible answer to this question could be replication
competent viruses. Along this line, a phase I clinical trial has been
recently completed, employing a double mutant herpes simplex
virus vector that selectively replicates in glioma cells but not
normal brain (Markert et al, 1999; Mineta et al, 1995). In addition,
ONYX-015, an E1B attenuated adenovirus that can selectively
replicate in cells with malfunctioning p53 (Bischoff et al, 1996).
Immunotherapy
The specifics of the immune response against gliomas are not very
well understood (Dietrich et al, 1997); nevertheless, more infor-
mation has been accumulating regarding the role of immunosup-
pressive cytokines such as TGF-b2 or interleukin (IL)-10 and Fas
ligand expression by glioma cells and remain to be translated into
useful therapeutic approaches, potentially after further develop-
ment of efficient gene transfer techniques. Immunotherapy
approaches tested to date include administration of IL-2 with LAK
or tumour infiltrating lymphocytes (TIL cells). Despite the encour-
aging results in animal models, human trials were met with little
success (Yoshida et al, 1990; Barba et al, 1989). In another
approach, radiolabelled anti-EGF receptor antibodies have been
injected into the tumour bed following resection of recurrent
gliomas. The dosimetry and toxicity of this approach have been
reported (Brady et al, 1992). Efficacy studies are ongoing.
A different monoclonal antibody approach involves the injec-
tion of a I131 labelled anti-tenascin monoclonal antibody into the
resection cavities of recurrent or newly diagnosed glioma patients
(Cokgor et al, 1999). Phase II trials are ongoing. Finally, the thera-
peutic potential of immunotoxins such as IL-4 bound
pseudomonas exotoxin A is under investigation. The latter
approach is based on the observation that 60–80% of high grade
gliomas express IL-4 receptor as compared to virtually no expres-
sion of the same receptor in normal brain (Weber et al, 1999).
In summary, nitrosourea-based chemotherapy in the adjuvant
setting has limited value in the management of patients with GBM
and its use should be individualized. Development of new drugs
should follow strict methodologic rules and take into consideration
other outcome measures such as quality of life. Anaplastic astrocy-
tomas are more chemosensitive than GBMs. Use of a nitrosourea-
based regimen in the adjuvant setting appears to be associated with
a survival benefit for anaplastic astrocytoma patients. For patients
with recurrent high-grade astrocytomas, options include
nitrosoureas, especially for previously untreated patients, the
imidotetrazine analogue, temozolomide, platinum-based regimens
and procarbazine. Participation in clinical trials should be particu-
larly encouraged in this setting. Oligodendrogliomas are
chemosensitive tumours. PCV is indicated in relapse and current
studies will define its role in the adjuvant setting. Innovative
strategies including small molecule pharmaceuticals, anti-invasion
agents, anti-angiogenesis agents and gene therapy approaches and
their interactions with ‘classic’ chemotherapy agents need to be
further investigated.
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